Choosing donor blood by RH genes for sickle cell disease
Tests donor blood picked by RH genes in sickle cell disease.
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- RH Genotype Matched RBC Transfusions
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 35 people, planned
- Started
- 30 Jan 2020
- Expected to end
- Oct 2029
- Type of study
- Interventional
- Treatments tested
- Red cell units that are genotype matched at the RHD and RHCE loci
- Record updated
- 27 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with sickle cell disease who need regular red blood cell transfusions. It tests giving donor red cells paired to the patient's RH genotype.
- Age
- 6 months and older.
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of any genotype, needing a period of regular red cell transfusion treatment.
Main reasons for not taking part
- A rare RH genotype that would make it hard to find enough red cell units
- Antigen-negative blood needs due to alloimmunization that would make it hard to find enough units
- Alloimmunization to the D antigen
- Rh alloimmunization where RH genotype paired blood would go against standard of care and blood bank protocols
- Parents/guardians or subjects who may not follow study schedules or procedures, in the investigator's opinion
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Subjects age >6 months
- Diagnosis of SCD, all genotypes
- Require a period of chronic red cell transfusion therapy
- Subject/parental/guardian permission (informed consent) and if appropriate, child assent
Who cannot take part
- Rare RH genotype that would preclude identification of sufficient RBC units
- Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units
- Alloimmunized to D antigen
- Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Stella Chou, MDTaking people
About the trial
What the trial wants to find out
To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.
The group in the trial
- RH genotype matched red cell transfusionsTreatment being tested
Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
Treatment: Red cell units that are genotype matched at the RHD and RHCE loci
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease
- Plain-language title
- Choosing donor blood by RH genes for sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 27 April 2026